For the quarter ending 2026-03-31, ASMB had -$27,330K decrease in cash & cash equivalents over the period. -$22,116K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue from a related party | 8,213 | 42,469 | 29,834 | - |
| ABIFive Three Six Six | - | - | 7,158 | - |
| ABIOne One Seven Nine | - | - | 5,047 | - |
| ABISix Two Five Zero | - | - | 4,617 | - |
| ABIFour Three Three Four | - | - | 919 | - |
| ABISeven Two Seven Two | - | - | 2,004 | - |
| Research And Discovery | - | - | 5,839 | - |
| Vebicorvir | - | - | 0 | - |
| Total external program expenses | - | - | 25,584 | - |
| Employee and contractor-related expenses | - | - | 19,365 | - |
| Facility and other expenses | - | - | 2,614 | - |
| Total research and development | 14,900 | 17,250 | 47,563 | - |
| General and administrative | 4,683 | 5,420 | 14,188 | - |
| Interest and other income, net | 2,291 | 2,291 | 3,705 | - |
| Income tax expense | - | 0 | 0 | - |
| Net loss | -9,079 | 22,090 | -9,196 | -19,016 |
| Depreciation and amortization | 26 | 32 | 32 | 65 |
| Stock-based compensation | 1,116 | 1,461 | 1,670 | 1,546 |
| Net accretion of investments in marketable debt securities | 789 | 828 | 631 | 887 |
| Non-cash rent expense | 204 | 204 | 209 | 438 |
| Realized gain on investments in marketable debt securities | - | 3 | - | - |
| Accounts receivable from collaboration with related party | -523 | 62 | 912 | 0 |
| Prepaid expenses and other current assets | 92 | 2,126 | 856 | -937 |
| Accounts payable | -42 | -512 | 940 | 158 |
| Accrued research and development expenses | -849 | -671 | 1,367 | -582 |
| Other accrued expenses | -5,085 | 2,021 | 2,321 | -3,455 |
| Deferred revenue from a related party | -7,828 | -7,174 | -9,877 | -19,045 |
| Operating lease liabilities | -202 | -195 | -200 | -356 |
| Net cash used in operating activities | -22,097 | 14,237 | -15,133 | -40,197 |
| Proceeds from maturities of marketable securities | 57,600 | 32,800 | 22,700 | 60,932 |
| Purchases of marketable securities | 62,963 | 11,553 | 180,929 | 37,352 |
| Purchases of property and equipment | 19 | 24 | 42 | 0 |
| Proceeds from the issuance of common stock under espp | - | 368 | 0 | 357 |
| Net cash (used in) provided by investing activities | -5,382 | 21,223 | -158,271 | 23,580 |
| Proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs | - | - | 0 | 0 |
| Proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs | - | 0 | 123,600 | - |
| Proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs | - | 0 | 42,785 | 0 |
| Proceeds from the exercise of warrants | - | 0 | 5,510 | - |
| Proceeds from the issuance of common stock under atm equity offering program, net of issuance costs | 0 | 0 | 0 | 1,922 |
| Proceeds from the exercise of stock options | 149 | 88 | 37 | 0 |
| Proceeds from the issuance of common stock and warrants in a registered direct offering, net of issuance costs | - | 0 | - | - |
| Net cash provided by financing activities | 149 | 456 | 171,932 | 2,279 |
| Net decrease in cash and cash equivalents | -27,330 | 35,916 | -1,472 | -14,338 |
| Cash and cash equivalents at the beginning of the period | 58,450 | 22,534 | 38,344 | - |
| Cash and cash equivalents at the end of the period | 31,120 | 58,450 | 22,534 | - |
ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC. (ASMB)